10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Sino-American company Brii Biosciences has announced positive data from the ACTIV-2 Phase III trial evaluating the combination of BRII-196 and BRII-198 in non-hospitalized COVID-19 patients. 26 August 2021
Pharma major Eli Lilly is expanding its portfolio in the field of targeted protein degradation forging a research and licensing deal with fellow USA-based biotech firm Lycia Therapeutics. 26 August 2021
Servier Pharmaceuticals, the US subsidiary of French drugmaker Servier, has won approval for Tibsovo (ivosidenib) in cholangiocarcinoma, a rare and aggressive form of cancer. 26 August 2021
US drugmaker Eagle Pharmaceuticals has entered into a worldwide licensing agreement with Swiss biotech Combioxin for the commercial rights to CAL02, an antitoxin agent ready for Phase IIb/III development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. 26 August 2021
Bain Capital has sold its 42.9%-plus convertible bonds in Kosdaq-listed botulinum toxin maker Hugel, reported the Korea JoongAng Daily and other media. 26 August 2021
A month ahead of the expected decision date, the US Food and Drug Administration yesterday approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH), says Danish biotech Ascendis Pharma. 26 August 2021
Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically-significant improvement in daily mean copper mobilization from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments 26 August 2021
Boston, USA-based pricing watchdog The Institute for Clinical and Economic Review (ICER) has published an update to its cost-effectiveness model for therapies in hereditary angioedema (HAE). 25 August 2021
A Texan biotech company focused on Alzheimer’s disease saw its share price slip by 24% during Wednesday morning’s trading after claims were posted about the firm’s scientific integrity online on Tuesday after market hours. 25 August 2021
The European Commission (EC) has approved Rinvoq (upadacitinib), an oral, selective and reversible JAK inhibitor from US pharma major AbbVie, for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. 25 August 2021
The International Vaccine Institute (IVI) has announced the first participant received Bharat Biotech International Ltd’s (BBIL) Chikungunya vaccine candidate (BBV87) in a Phase II/III clinical trial in Costa Rica. 25 August 2021
Research from industry analyst GlobalData suggests that HIV drugs containing tenofovir alafenamide (TAF) are set to book sales over $15 billion by the year 2029. 25 August 2021
For spinal muscular atrophy (SMA) Awareness Month, we take a look at advances in the pharmacological treatment of this rare hereditary disease. 25 August 2021
Approval has been granted for the combination of Opdivo (nivolumab) intravenous infusion and Cabometyx (cabozantinib s-malate) tablets in Japan for the treatment of unresectable or metastatic renal cell carcinoma (RCC), for a partial change in approved items of the manufacturing and marketing approval. 25 August 2021
India's Council of Scientific and Industrial Research (CSIR)'s constituent Central Drug Research Institute (CDRI) has teamed up with domestic drugmaker Marc Laboratories to develop a compound for treating heart attack and stroke. 25 August 2021
UK-based T cell receptor (TCR) biotech firm Immunocore yesterday announced that regulators in the USA and European Union have each accepted applications for the approval of tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive adult patients with metastatic uveal melanoma (mUM). 25 August 2021
The Russian Ministry of Health spent more than 26.1 billion roubles ($351 million) on the procurements of drugs against HIV this year, an increase of 10% compared with the year earlier, according to recent statements by Ministry’s press-service, reports The Pharma Letter’s local correspondent. 25 August 2021
The city of St Petersburg will retain its status as one of the leading centers of pharmaceutical production in Russia, due to the almost doubling of revenue of pharmaceutical companies operating their facilities within the territory of the city this year. 25 August 2021
Children in England are set to be the first in the world to be offered direct acting antiviral (DAA) tablets for hepatitis C, as part of National Health Service (NHS) plans to eradicate the disease entirely. 24 August 2021
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024